Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624319 | 0.86 | DHFR (0.41) | NPSR1TLR7DHFRTLR8 | |
| SCHEMBL10310939 | 0.82 | TLR7 (0.44) | NPSR1TLR7 | |
| SCHEMBL16624323 | 0.79 | TLR7 (0.39) | NPSR1TLR7DHFRTLR8 | |
| SCHEMBL16624324 | 0.78 | SMN1; SMN2 (0.46) | NPSR1NPC1RAB9ASMN1; SMN2DHFR | |
| SCHEMBL16624362 | 0.76 | HSP90AB1 (0.41) | SMN1; SMN2DHFR | |
| SCHEMBL18052639 | 0.74 | TLR7 (0.37) | NPSR1TLR7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16624329 | 0.74 | NPSR1 (0.40) | NPSR1TLR7DHFRTLR8 | |
| SCHEMBL22523838 | 0.72 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL8771412 | 0.71 | ALDH1A1 (0.43) | NPC1RAB9ADHFR | |
| SCHEMBL4279450 | 0.71 | TRPA1 (0.44) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | NPSR1 1487/4885TLR7 87/4885NPC1 924/4885 |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | NPSR1 1487/4885TLR7 87/4885NPC1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.